H. A. Sater

Nascent prostate cancer heterogeneity drives evolution and resistance to intense hormonal therapy

P. Choyke, M. Merino, S. Harmon, 2020, medRxiv.

A Case Report of Inflammatory Syndrome Presenting as Tumor Lysis Syndrome after Single Dose of Nivolumab

H. A. Sater, Reena Patel Brian Sulliva, Jigarkumar Parikh, 2017 .

P854 Construction of the immune landscape of durable response to checkpoint blockade therapy by integrating publicly available datasets

Daniel K. Wells, V. Thorsson, Y. Najjar, 2020, Journal of Immunotherapy for Cancer.

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells

J. Schlom, C. Van Waes, J. Friedman, 2020, bioRxiv.

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies

S. Salas, J. Schlom, B. Cho, 2020, Journal for ImmunoTherapy of Cancer.